20170406 Telix Logo.png
EAU Updates Guidance for PSMA-PET Imaging
21 mars 2022 01h28 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the updated 2022 ‘Guidelines on Prostate...
20170406 Telix Logo.png
Telix Enters Commercial Distribution Agreement for Illuccix® in Australia
15 févr. 2022 17h39 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a commercial distribution agreement with...
20170406 Telix Logo.png
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
07 févr. 2022 18h08 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that...
20170406 Telix Logo.png
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
27 janv. 2022 16h41 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
20170406 Telix Logo.png
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®
19 déc. 2021 16h47 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a global biopharmaceutical company focused on the development...
20170406 Telix Logo.png
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain
07 déc. 2021 17h42 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and MADRID, Spain, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
20170406 Telix Logo.png
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
30 nov. 2021 16h45 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and PORTO ALEGRE, Brazil, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory...
20170406 Telix Logo.png
NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed
14 nov. 2021 15h59 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first Australian patient has been dosed in the...
20170406 Telix Logo.png
Australian TGA Approves Illuccix® for Prostate Cancer Imaging
01 nov. 2021 19h25 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has...
20170406 Telix Logo.png
Second Industry Body Updates Guidance for Use of PSMA PET Imaging
20 sept. 2021 20h31 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has today welcomed the Society of Nuclear Medicine and...